<code id='6A37ABF834'></code><style id='6A37ABF834'></style>
    • <acronym id='6A37ABF834'></acronym>
      <center id='6A37ABF834'><center id='6A37ABF834'><tfoot id='6A37ABF834'></tfoot></center><abbr id='6A37ABF834'><dir id='6A37ABF834'><tfoot id='6A37ABF834'></tfoot><noframes id='6A37ABF834'>

    • <optgroup id='6A37ABF834'><strike id='6A37ABF834'><sup id='6A37ABF834'></sup></strike><code id='6A37ABF834'></code></optgroup>
        1. <b id='6A37ABF834'><label id='6A37ABF834'><select id='6A37ABF834'><dt id='6A37ABF834'><span id='6A37ABF834'></span></dt></select></label></b><u id='6A37ABF834'></u>
          <i id='6A37ABF834'><strike id='6A37ABF834'><tt id='6A37ABF834'><pre id='6A37ABF834'></pre></tt></strike></i>

          comprehensive

          comprehensive

          author:focus    Page View:51116
          In this photo illustration, Farxiga, Xarelto, Entresto, and Eliquis are made available to customers at the New City Halsted Pharmacy on August 29, 2023 in Chicago, Illinois. These are 4 of 10 prescription drugs that will be subject to Medicare price negotiations under the Inflation Reduction Act. The other drugs include Jardiance, Enbrel, Januvia, Imbruvica, Stelara and Fiasp.
          Scott Olson/Getty Images

          WASHINGTON  — The Biden administration is making its opening offers to pharmaceutical companies in its brand-new Medicare drug price negotiation program on Thursday, administration officials said. And that’s about all they said.

          The offers will not be made public unless a manufacturer chooses to publicly disclose information about the talks, a senior administration official said. Companies have until March 2 to either accept the government’s offer or propose a counteroffer. The Biden administration will publish the final prices by Sept. 1 of this year after the negotiation process ends. 

          advertisement

          The negotiated prices won’t take effect until 2026. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          knowledge

          Moonlake's readout produced a cash windfall. Risks remain
          Moonlake's readout produced a cash windfall. Risks remain

          MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

          read more
          Private equity could exacerbate cardiology's overuse problem, experts fear
          Private equity could exacerbate cardiology's overuse problem, experts fear

          AdobeCoronarystentingis,bysomemeasures,themostoverusedprocedureinhospitals.Theproblemcoststhehealths

          read more
          Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
          Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

          AdobeSometimes,anappleadayreallyisjustwhatthedoctorordered.Andforthepastseveralyears,organizationsli

          read more

          Hospitals consider fixing cancer drug shortages on their own

          CivicaRxisconsideringamoveintochemotherapiesamiddrugshortages.AdobeWASHINGTON—Anonprofitformedbyhosp